Molecular structure of Madrasin, CAS Number: 374913-63-0
Madrasin (CAS 374913-63-0)
Alternate Names:
SMR000135614 MLS000530636 CHEMBL1523019
CAS Number:
374913-63-0
Molecular Weight:
311.34
Molecular Formula:
C16H17N5O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Madrasin (CAS 374913-63-0) References
- Identification of small molecule inhibitors of pre-mRNA splicing. | Pawellek, A., et al. 2014. J Biol Chem. 289: 34683-98. PMID: 25281741
- Modulating splicing with small molecular inhibitors of the spliceosome. | Effenberger, KA., et al. 2017. Wiley Interdiscip Rev RNA. 8: PMID: 27440103
- A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. | Shi, Y., et al. 2017. Bioorg Med Chem Lett. 27: 406-412. PMID: 28049589
- Flow cytometric analysis identifies changes in S and M phases as novel cell cycle alterations induced by the splicing inhibitor isoginkgetin. | Vanzyl, EJ., et al. 2018. PLoS One. 13: e0191178. PMID: 29338026
- XAB2 depletion induces intron retention in POLR2A to impair global transcription and promote cellular senescence. | Hou, S., et al. 2019. Nucleic Acids Res. 47: 8239-8254. PMID: 31216022
- Cross-species identification of PIP5K1-, splicing- and ubiquitin-related pathways as potential targets for RB1-deficient cells. | Parkhitko, AA., et al. 2021. PLoS Genet. 17: e1009354. PMID: 33591981
- Splicing is an alternate oncogenic pathway activation mechanism in glioma. | Siddaway, R., et al. 2022. Nat Commun. 13: 588. PMID: 35102191
- Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia. | Morales, ML., et al. 2023. Leukemia. 37: 1649-1659. PMID: 37422594
- Cytoskeleton remodeling mediated by circRNA-YBX1 phase separation suppresses the metastasis of liver cancer. | Liu, B., et al. 2023. Proc Natl Acad Sci U S A. 120: e2220296120. PMID: 37459535
- Nuclear RNA-related processes modulate the assembly of cytoplasmic RNA granules. | Angel, M., et al. 2024. Nucleic Acids Res. 52: 5356-5375. PMID: 38366783
Inhibitor of:
2810403A07Rik, 9G8, Cdc40, CELF6, CROP, CWC15, DDX23, DDX39, DDX46, FUSIP1, GPATCH2, GPATCH8, MFAP1A, PRKRIP1, PRP8, PRPF3, PRPF31, PRPF38B, RBM14, RBM17, RBM18, RBM22, RBM25, RBM34, RBM9, RNPC3, RP11-430L17.1, RP11-592B15.4, SAP 145, SAP 155, SAP 49, SAP 61, SAP 62, SART-1, SDCCAG10, SF3B10, SFRS12IP1, SFRS16, SFRS2IP, SFRS8, Sm D2, SmB, SMNDC1, SMU1, SNRNP48, SNRPC, SRm300_Srrm2, SRp30a, SRp30b, SRrp35, TFIIIC90, TSEN54, U11/U12 snRNP 20K, U11/U12 snRNP 25, U2 snRNP A, U2 snRNP B, U2AF1L3, ZC3H14, ZCCHC8, ZNHIT2, ZRSR1, and ZRSR2.Activator of:
Gemin6, GPATCH4, hnRNP H3, PHF5A, SF4, SFRS11, U2 snRNP B, and U2 snRNP B′′.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Madrasin, 100 mg | sc-507563 | 100 mg | $750.00 |